TB-500: Research Overview of the Thymosin Beta-4 Fragment
TB-500 is the name used for a short synthetic peptide modelled on one active region of thymosin beta-4 (Tβ4), a 43-amino-acid protein present in most animal and human cells. Analytical chemistry papers describe TB-500 as the seven-residue sequence LKKTETQ, which corresponds to positions 17 to 23 of Tβ4, with an acetyl group added to its starting end: Ac-LKKTETQ (Esposito 2012; Ho 2012).
That distinction matters when reading the literature. Most of the tissue-repair research people associate with TB-500 was carried out with the full-length Tβ4 protein, not with the seven-residue fragment.
TB-500 and Thymosin Beta-4 Are Not the Same Molecule
- Thymosin beta-4: 43 amino acids, roughly 4.9 kDa. It is one of the main proteins that bind single actin units (G-actin) inside cells, which helps control how the cell's internal skeleton is built and taken apart (Safer 1991).
- TB-500 (Ac-LKKTETQ): 7 amino acids, roughly 0.89 kDa. The LKKTETQ stretch sits inside the part of Tβ4 that binds actin, which is why it was chosen as the basis for a smaller synthetic version (Ho 2012).
Because the name is used loosely in the market, the identity result on a batch certificate (mass spectrometry or a matched HPLC reference) is the most reliable way to confirm which molecule a vial contains.
Studied Mechanisms (Mostly From Full-Length Tβ4)
- Actin binding and cell movement — Tβ4 holds G-actin in reserve, which is linked to how readily cells change shape and migrate (Safer 1991).
- Wound-model research — in a rat full-thickness skin wound model, Tβ4 applied to the wound or given intraperitoneally increased re-epithelialization by 42% over saline controls at day 4 and by up to 61% at day 7, with more collagen deposition and new blood vessel growth in the treated wounds. The same study found Tβ4 increased keratinocyte migration two- to three-fold in a cell-culture assay (Malinda 1999).
- Cardiac cell signalling — Tβ4 was shown to form a complex with the proteins PINCH and integrin-linked kinase, activating the survival kinase Akt. In mice after coronary artery ligation, Tβ4 treatment was associated with better early heart-muscle cell survival and cardiac function (Bock-Marquette 2004).
- Corneal models — in an alkali-injury model of the cornea, Tβ4 was reported to promote wound closure and reduce inflammation (Sosne 2002).
A broad review of this body of work, written by researchers who helped characterize Tβ4, is Goldstein 2012.
What Studies of the Fragment Itself Show
Published research on Ac-LKKTETQ as a separate molecule is much thinner, and most of it comes from anti-doping laboratories, because the product has been misused in horse racing and sport.
- Identification — a Belgian anti-doping group synthesized Ac-LKKTETQ, confirmed it as the active ingredient in a TB-500 product by high-resolution mass spectrometry, and proposed a detection method for plasma and urine (Esposito 2012).
- Detection in horses — a Hong Kong racing laboratory developed a liquid chromatography-mass spectrometry method that detects Ac-LKKTETQ and its breakdown products in equine plasma and urine (Ho 2012).
- Metabolism and activity — a 2024 study traced how TB-500 is broken down in human serum, in enzyme systems and in rats. The main early breakdown product was Ac-LK, and Ac-LKK was detectable for up to 72 hours in rats. In a fibroblast scratch assay, only the breakdown product Ac-LKKTE showed significant wound-closure activity, and the authors suggest earlier reported activity of TB-500 may come from this metabolite rather than the parent peptide (Rahaman 2024).
Human Research Status
Full-length Tβ4 has been studied in clinical trials as an eye-drop formulation for ocular surface conditions (reviewed in Sosne 2018). A PubMed search in October 2026 found no published clinical trials of the TB-500 fragment itself.
Handling in the Lab
TB-500 is supplied as a lyophilized powder. Unopened vials are best stored at −20 °C, protected from light and moisture. After reconstitution with bacteriostatic water, keep the solution at 2–8 °C and avoid repeated freeze–thaw cycles. Our reconstitution guide and Reconstitution Calculator cover the solution-concentration math.
See the TB-500 product page for current batch specifications, or the BPC-157 + TB-500 blend. For the other compound in that blend, read our BPC-157 research overview.
References
- Esposito S, et al. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Drug Test Anal. 2012;4(9):733-8. PubMed 22962027
- Ho EN, et al. Doping control analysis of TB-500, a synthetic version of an active region of thymosin β4, in equine urine and plasma by liquid chromatography-mass spectrometry. J Chromatogr A. 2012;1265:57-69. PubMed 23084823
- Safer D, Elzinga M, Nachmias VT. Thymosin beta 4 and Fx, an actin-sequestering peptide, are indistinguishable. J Biol Chem. 1991;266(7):4029-32. PubMed 1999398
- Malinda KM, et al. Thymosin beta4 accelerates wound healing. J Invest Dermatol. 1999;113(3):364-8. PubMed 10469335
- Bock-Marquette I, et al. Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature. 2004;432(7016):466-72. PubMed 15565145
- Sosne G, et al. Thymosin beta 4 promotes corneal wound healing and decreases inflammation in vivo following alkali injury. Exp Eye Res. 2002;74(2):293-9. PubMed 11950239
- Goldstein AL, et al. Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther. 2012;12(1):37-51. PubMed 22074294
- Rahaman KA, et al. Simultaneous quantification of TB-500 and its metabolites in in-vitro experiments and rats by UHPLC-Q-Exactive orbitrap MS/MS and their screening by wound healing activities in-vitro. J Chromatogr B. 2024;1235:124033. PubMed 38382158
- Sosne G. Thymosin beta 4 and the eye: the journey from bench to bedside. Expert Opin Biol Ther. 2018;18(sup1):99-104. PubMed 30063853